Company Description

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.

The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older.

It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025.

Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Pelthos Therapeutics Inc.

Country	United States
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Scott Plesha

Contact Details

Address: 4020 Stirrup Creek Drive, Suite 110 Durham, North Carolina 27703 United States
Phone	877 265 8266
Website	pelthos.com

Stock Details

Ticker Symbol	PTHS
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001919246
ISIN Number	US1711261057
Employer ID	86-3335449
SIC Code	2836

Key Executives

Name	Position
Scott M. Plesha	Chief Executive Officer, President and Director
Francis Knuettel II, M.B.A.	Chief Financial Officer
Sai Rangarao M.B.A.	Chief Commercial Officer

Latest SEC Filings

Date	Type	Title
Nov 25, 2025	DEF 14A	Other definitive proxy statements
Nov 19, 2025	D	Notice of Exempt Offering of Securities
Nov 14, 2025	SCHEDULE 13G/A	Filing
Nov 14, 2025	PRE 14A	Other preliminary proxy statements
Nov 14, 2025	SCHEDULE 13G	Filing
Nov 13, 2025	8-K	Current Report
Nov 13, 2025	10-Q	Quarterly Report
Nov 10, 2025	SCHEDULE 13D/A	Filing
Nov 7, 2025	8-K	Current Report
Oct 14, 2025	8-K	Current Report

View All SEC Filings